Janssen will conduct Risperdal-Zyprexa comparative trial in response to Lilly study presented at ACNP.
Executive Summary
JANSSEN PLANNING RISPERDAL HEAD-TO-HEAD TRIAL WITH ZYPREXA, the company said in response to the announcement of the interim results from a Lilly-conducted comparative schizophrenia trial. The study presented at the American College of Neuropsychopharmacology in San Juan, Puerto Rico on Dec. 11 by Lilly's Pierre Tran, MD, concluded that Zyprexa (olanzapine) "significantly outperforms risperidone [Risperdal]" in efficacy, extrapyramidal symptom incidence and minimal prolactin elevation.